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Abstract 
Deep endometriosis, occurring approximately in 1% of women of reproductive age, represents the 
most severe form of endometriosis. It causes severe pain in the vast majority of affected women and 
it can affect the bowel and the urinary tract. Hormonal treatment of deep endometriosis with 
progestins, such as norethindrone acetate or dienogest, or estroprogestins is effective in relieving 
pain in more than 90% of women at one year follow up. Progestins and estroprogestins can be 
safely administered in the long-term, may be not expensive and are usually are well tolerated. 
Therefore, they should represent the first-line treatment of deep endometriosis associated pain in 
women not seeking natural conception. However, hormonal treatment is ineffective or not tolerated 
in about 30% of women, the most common side effects being erratic bleeding, weight gain, 
decreased libido and headache. Surgical excision of deep endometriosis is mandatory in presence of 
symptomatic bowel stenosis, ureteral stenosis with secondary hydronephrosis, and when hormonal 
treatments fail. Surgical treatment is similarly effective as compared to hormonal treatment in 
relieving dismenorhea, dyspareunia and dyschezia at one year follow up in more than 90% of 
women with deep endometriosis. Surgical removal of the nodules may require resection of the 
bowel, ureter or bladder, with possible severe complications such as rectovaginal or ureterovaginal 
fistula and anastomotic leakage. A thorough counsel with the patient is necessary in order to pursue 
a therapeutic plan centered not on the endometriotic lesions, but on the patient’s symptoms, 
priorities and expectations. 
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Introduction 
The endometriotic disease is differentiated in three different forms: ovarian cysts, superficial 
peritoneal lesions and deep infiltrating lesions. Deep infiltrating endometriosis, occurring 
approximately in 1% of women of reproductive age (1), represents the most severe form of the 
disease. In the vast majority of women, deep endometriotic lesions involve the posterior 
compartment, affecting the uterosacral ligaments, the Douglas pouch, the anterior rectal wall and 
the posterior vaginal wall, with estimated prevalence of bowel involvement between 7% and 19% 
(2). Less frequently, deep endometriosis may affect the ureter and the bladder. However, according 
to recent findings, the involvement of the urinary tract in women with deep endometriosis may be 
more frequent than presumed and as high as 19% (3) or even 53% (4).  
Deep infiltrating endometriosis is associated with severe pain in more than 95% of women (5). 
Typically, women experience pain in the form of dysmenorrhea, deep dyspareunia or nonmenstrual 
pelvic pain. Symptoms and signs of infiltrative bowel lesions include severe constipation, 
dyschezia, menstrual diarrhea, menstrual hematochezia, and pain radiation to the perineum (6). 
Bladder endometriosis is usually associated with catamenial mictalgia, frequency, urgency, or 
vesical tenesmus. Although women with ureteral endometriosis may present with colicky flank pain 
or gross hematuria, as many of 50% of them may be asymptomatic. Ureteral endometriosis 
represents therefore the most insidious form of the disease, because it may cause silent loss of renal 
function (5). 
Treatment of deep endometriosis can be either surgical, aiming at restoring the normal anatomy by 
removing endometriotic lesions, or hormonal, aiming at inducing a hypo-estrogenic state, atrophy 
or quiescence of endometrioc lesions, and a reduction of the chronic peritoneal inflammatory status. 
In the present paper, we will describe the factors influencing the choice between a surgical or a 
hormonal treatment for deep endometriosis. 
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Clinical assessment: anatomical characteristics of the disease 
Deep endometriosis has a typical multi-focal presentation (7). In order to plan an appropriate 
surgical or medical treatment of this condition, ultrasonography and MRI are useful tools for 
assessing the number, size and anatomical localization of the endometriotic nodules (5,8). However, 
MRI has not been demonstrated to be more accurate and reliable than transvaginal or transrectal 
ultrasonography. Moreover, transvaginal and transrectal ultrasonography have the advantages over 
MRI of being less expensive, more easily repeatable and allowing pushing pelvic organs with the 
probe for the evaluation of mobility and elicited pain.  
The preoperative mapping of endometriotic lesions provides the surgeon many important 
informations (9). Transrectal sonography can identify the normal rectal wall layers and detect rectal 
endometriosis as endometriotic infiltration of the muscularis layer; however, it is less accurate in 
assessing the involvement of the submucosal and mucosal layer (10, 11). In addition, transrectal 
sonography is useful for the assessment of the level of bowel lesions. In fact, low rectal nodules, 
that are associated with a higher rate of surgical complications as compared to upper rectal and 
sigmoid nodules, are visualized below the level of the insertion of the uterosacral ligaments on the 
uterine cervix. Moreover, transrectal sonography can assess the lowest limit of the rectal nodule by 
measuring its distance from the anus (12).  
The dimensions of deep nodules affect the complexity of the surgical procedure. Big nodules of 
>3cm and those who extend laterally in the parametrium are more likely to affect the ureter and to 
caue urinary retention after surgery (5, 13). However, at transvaginal ultrasound, the ureteral course 
can by directly evaluated for possible endometriotic infiltration from the renal pelvis down to the 
anterior parametrium. When ureteral involvement is suspected, hydronephrosis must be ruled oud 
by means of renal ultrasound. In presence of ureteral stenosis associated with hydronephrosis, a 
preoperative ureteral stent is required, when feasible, and the surgical procedure is planned 
accordingly with the intraoperative availability of an expert urologist (14). Endometriotic bladder 
lesions are easily seen at transvaginal or transabdominal ultrasound with a partially replete bladder. 
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Cystoscopy rules out a transitional epithelium carcinoma and allows to measure the distance 
between the endometriotic lesion and the ureteral meatus, because the removal of the rare nodules 
that affect or are closer than 2 cm to the ureteral meatus is more difficult, associated with a higher 
rate of complications, and may require ureteroneocystostomy. 
A double-contrast enema is particularly useful for the evaluation of the degree and length of bowel 
occlusion in case of lesions higher than the rectum, i.e. endometriotic nodules of the high 
rectosigmoid or sigmoid colon (5). 
 
Surgical treatment: technique, outcome and complications 
When a deep infiltrating nodule of the posterior compartment is present, the surgical procedure 
entails performing bilateral ureterolysis with lateralization of the ureters, entering the pararectal 
spaces and subsequently separating the rectum from the posterior aspect of uterine cervix and 
vagina restoring the normal anatomy of the Douglas pouch. The radical excision of the nodule may 
require the removal of a portion of the vagina and/or the bowel (15). The techniques for removing 
an endometriotic nodule from the rectum or rectosigmoid include the shaving of the nodule, i.e. 
without entering the bowel mucosa, the discoid resection or the segmental resection. It has been 
suggested that women with a bowel occlusion of >50% or longer than 2–3 cm should be scheduled 
for elective bowel resection, whereas all other women should undergo excision of the nodule (5). In 
most cases, however, surgeons decide what procedure to perform according to the intraoperative 
findings, and not before surgery. A protective colostomy is required in 10%-14% of women 
undergoing bowel surgery for deep endometriotic lesions (12). 
Ureterolysis is adequate for treating ureteral endometriosis in many patients (14); however, a 
ureteral resection is necessary in case of hydroureteronephrosis with intrinsic localization of the 
disease (16). Segmental bladder resection represents the standard treatment for vesical 
endometriosis. 
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The outcome of surgical treatment for deep endometriosis is difficult to assess, because it is 
influenced by numerous variables including severity of the disease, number and location of 
endometriotic nodules, degree of infiltration of the bowel or the urinary tract, surgeon’s criteria for 
performing segmental bowel resection instead of shaving or discoid resection and overall 
experience of the surgical team. According to a systematic review evaluating 34 articles describing 
1889 procedures, segmental bowel resection is effective in reducing dismenorhea, dyspareunia and 
dyschezia at one year follow up in more than 90% of women. Pain relief after surgery was 
consistent with 71.4–93.6% of women being pain free after 1 year of follow-up (table 1). In this 
series, treatment of deep endometriosis with bowel resection was associated with a 22% overall risk 
of complications, with an incidence of major complications of 11%, including anastomotic leakage, 
rectovaginal fistula and severe bowel obstruction (Table 2). A repeat procedure within 5 years from 
primary surgery because of recurrence of pain was reported in about one in five women (19%) who 
underwent bowel resection (17). 
Another review has evaluated the rate of complications associated with treatment of ureteral 
endometriosis in the form of ureterolysis (176 women), ureteral anastomosis (28 women) and 
ureteroneocystostomy (39 women) with an overall rate of major complications of 9%, including 
ureteral or uretero-vaginal fistula and stenosis persistence/recurrence (table 2) (18).  
As for bladder endometriosis, in a series of 69 patients (21 with partial cystectomy, 24 with nodule 
resection without bladder invasion and 24 with bladder nodule coagulation and ablation) 92.7 % of 
the women were asymptomatic or reported improvement in symptoms at a median follow up of 60 
months, and no intraoperative complications were noted (19). 
 
Hormonal treatment: rationale and available drugs 
In the last decade, the substantial progress of diagnostic imaging has allowed a reliable noninvasive 
diagnosis of deep endometriosis, i.e. without the need for surgical and histological confirmation, 
thus opening the possibility to shift first-line treatment of endometriosis from surgery to medical 
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therapy. Hypo-estrogenizing drugs induce atrophy of the ectopic endometrium and possibly allow 
control of pain symptoms by reducing the intra- and peri-lesional inflammation of endometriotic 
nodules, with diminished production of prostaglandins and cytokines and thus less stimulation of 
pain fibers. However, since the discontinuation of hormonal medications for endometriosis is 
associated with the recovery of endometrial function under the influence of ovarian steroids and 
thus with the recurrence of pain symptoms, such medications need to be administered for long 
periods (20). Therefore, provided that the efficacy in the control of pain is comparable between all 
the available hormonal compounds (21, 22), the choice of treatment is primarily based on safety in 
the long-term, side effects and costs. Basing upon such principles, progestogens and estroprogestins 
represent the first choice for the medical treatment of endometriosis (23, 24). A detailed description 
of second-line medications for rectovaginal endometriosis (including GnRH-a plus add back 
therapy, vaginal danazol and aromatase inhibitors) is beyond the scopes of the present paper. A 
recent paper has reviewed the available evidence on this topic (2). 
 
Progestins and estroprogestins: efficacy and side effects 
Norethindrone acetate (NETA) and dienogest are the progestins that have been more extensively 
evaluated for the treatment of endometriosis. Both of them are 19-nortestosterone derivative 
progestins and the pharmacological differences between the two compounds are limited: NETA has 
‘‘strongly effective’’ progestogenic activity and androgenic activity, whereas dienogest has 
‘‘effective’’ progestogenic activity and antiandrogenic activity (25, 26). 
The only randomized controlled trail available, evaluating the medical treatment of 
rectovaginal endometriosis, has compared oral NETA 2.5 mg daily with an oral contraceptive pill 
containing ethinyl estradiol 0.01 mg and cyproterone 3 mg (27). In the NETA group, women who 
were free of symptom at 12-month follow up ranged between 74% for dyspareunia and 92% for 
dysmenorrhea (table 3). Comparable results were observed in the estrogen-progestin combination 
group.  
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Another study showed that after 12 month of treatment with NETA, 40 women with 
rectosigmoid endometriosis, who were still symptomatic following non-radical surgery, 
experienced significant improvements in diarrhea, intestinal cramping, passage of mucus with stool, 
and cyclic rectal bleeding (28).  
In 2014, a 24-week open-label prospective study suggested that treatment with dienogest 
might improve pain symptoms in women with rectovaginal endometriosis who had pain persistence 
after 6-months of NETA therapy (29). 
A recent study has shown that dienogest is as effective as NETA in improving pain 
symptoms in women with rectovaginal endometriosis. Because the two molecules are similar and 
because all hormonal therapies for endometriosis have proven effective without significant 
differences among different drugs (21, 22), this outcome was expected. However, this study has 
thoroughly evaluated the tolerability of the two drugs. No major adverse events were recorded. Side 
effects were experienced by 55% of women in the NETA group and 41% of women in the 
dienogest group, the most frequent being weight gain, spotting and decreased libido (Table 4). 
Overall tolerability was significantly better in women using dienogest than in those using 
norethindrone acetate. However, the overall effectiveness was higher with NETA, owing to limited 
compliance with dienogest therapy resulting from the high cost of this drug (30). 
Other studies have demonstrated that women with rectovaginal endometriosis- associated 
pain benefit from treatment with non-oral contraceptives such as the contraceptive vaginal ring and 
the contraceptive patch (31), a desogestrel-only pill (32) and the levonorgestrel-releasing 
intrauterine device (33). Continuous combined oral contraceptives (34) and dienogest (35) proved 
effective in improving urinary symptoms associated with bladder endometriosis. 
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Counselling the patient: surgical or medical treatment? 
Available data suggest that surgical excision and medical treatment are similarly effective in 
improving pain symptoms associated with deep endometriosis. Accordingly, a study that have 
formally compared surgery with daily administration of NETA 2.5 mg, found no significant 
between-group difference in the severity of dyspareunia at 12-month follow up in women with 
rectovaginal endometriosis (36). Women in the surgery group experienced a marked and rapid 
short-term relief followed by partial recurrence of pain, whereas women in the NETA group 
reported a gradual and progressive improvement of dyspareunia throughout the study period. 
Progestogens or estroprogestins are effective in relieving deep endometriosis related pain and their 
long-term administration is safe (37) and may not be expensive. Basing upon current knowledge, 
these hormones represent the first-line medical treatment for deep endometriosis related pain. 
Although untoward effects are common, occurring in more than 50 % of women, they are usually 
well tolerated by the majority of women (30). Moreover, when side effects are poorly tolerated, it is 
possible to switch to a different available formulation that may be accepted.  
Surgical excision of deep endometriotic nodules is necessary when they cause bowel stenosis 
associated with subocclusive symptoms or ureteral stenosis causing hydronefrosis. In addition, 
surgery is necessary in the approximately one woman out of three in whom hormonal treatments 
fail (36). The reasons for hormonal treatment failure include: ineffectiveness in relieving pain; the 
onset of unbearable side effects, more frequently represented by erratic bleeding, weight gain, 
decreased libido and headache; the presence of contraindications to hormonal treatment such as 
hypertension, migraine with aura, previous venous thrombosis or depression (37); the woman 
refusing to take chronic medications.  
Eventually, in the vast majority of cases, the choice of surgical versus medical treatment of deep 
endometriosis must be shared between the physician and the woman, after she has been adequately 
informed of the risks and benefits associated with both options. Each individual woman must have 
clear in mind that endometriotic deep lesions are benign and usually not progressive (38) and 
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therefore, the choice of treatment should focus on her symptoms and expectations rather than the 
eradication of the disease. The information about the likelihood of pain relief after surgery or 
medical therapy should be as detailed as possible and the rates of both international and institutional 
surgical complications should be provided (39). 
Finally, the desire of pregnancy and the woman’s age are two important variables influencing the 
therapeutic plan. In women seeking pregnancy, IVF should be considered because currently 
available hormonal treatments are all contraceptive. In case of repeated IVF failures, surgery is 
indicated (40). However, it has been pointed out that medical therapy may play a role also in 
women seeking pregnancy. In fact, a prolonged medical therapy that is temporarily discontinued to 
allow IVF attempts may be associated with an acceptable quality of life and it may even increase 
the IVF-associated pregnancy rate (41-43). As for the role of age, a more radical treatment seems to 
be justified in younger patients for the possible more aggressive nature of the disease and the higher 
recurrence rates (44), whereas a more conservative management may be pursued among women 
approaching the menopause (40). 
In conclusion, symptomatic deep endometriosis is a complex clinical condition, usually associated 
with chronic pelvic pain, which can adversely affect women’s quality of life, sexual satisfaction and 
the possibility to conceive. In addition, deep endometriotic lesions can undermine the anatomical 
and functional integrity of vital organs such as bowel, ureter and bladder. The treatment of this 
condition may require chronic hormonal medications, complex surgical procedures, assisted 
reproduction techniques and psychological support. The role of the physician is to guide the woman 
across all therapeutic possibility in order to resolve or minimize the impact of the disease and 
possibly helping her to fulfil her expectations. 
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